‘Why Wouldn’t You Use This?’: Teva Plots $2bn LAI Schizophrenia Franchise
Israeli Firm Eyeing Potential To Treat A Further 125,000 Patients In US
Teva has laid out an ambitious goal for its long-acting injectable schizophrenia drugs to grow into a $2bn franchise, ahead of the planned US filing of olanzapine later this year.
